High-Grade Endometrial Stromal Sarcoma with NTRK Fusion and Response to Larotrectinib: A Case Report
Journal of Clinical Medicine · 23.06.2026 · 15 (13) · 4887
DOI: 10.3390/jcm15134887 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.06.2026. Verfasst von Tomer Bar-Noy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
High-grade endometrial stromal sarcoma (HGESS) is a rare and aggressive uterine mesenchymal tumor with a significant potential for recurrence and metastasis. Advances in molecular pathology have identified recurrent gene fusions involving the neurotrophic tyrosine receptor kinase (NTRK) genes, which are crucial for tumorigenesis. The identification of NTRK fusions has significant therapeutic implications, as targeted therapies such as Larotrectinib, a selective tyrosine receptor kinase (TRK) inhibitor, have demonstrated remarkable efficacy in NTRK fusion-positive tumors across various tumor histologies. Case Presentation: This report depicts the case of a 42-year-old woman with HGESS harboring an NTRK fusion diagnosed by histopathology and immunohistochemistry after undergoing a vaginal myomectomy. She subsequently underwent a robotic total hysterectomy, bilateral salpingo-oophorectomy, and bilateral lymph node dissection. Following a four-year disease-free interval, HGESS relapsed. The patient received three cycles of gemcitabine plus docetaxel. Subsequent CT imaging indicated progression of the pelvic mass. Molecular testing identified an NTRK fusion. Accordingly, larotrectinib was initiated in the setting of progressive disease. After three months, imaging demonstrated a significant decrease in the pelvic mass and near-complete radiographic resolution of the pulmonary nodules. The patient remained on larotrectinib, with January 2024 imaging showing no evidence of recurrence.
Conclusions
The case presented highlights a personalized approach based on molecular profiling, and the successful use of larotrectinib, a TRK inhibitor, after the identification of an NTRK fusion-positive HGESS, emphasizing the importance of molecular diagnostics and targeted therapy in managing this rare malignancy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
- Department of Obstetrics and Gynecology, McGill University, Montreal, QC H4A 3J1, Canada.
- Department of Pathology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
- Lady Davis Institute for Cancer Research, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
ORCID-Profile: Tomer Bar-Noy, Melica Nourmoussavi Brodeur, Shannon Salvador
Zitieren
APA
Bar-Noy, T., Lozano-Franco, R., Nagaria, T. S., Brodeur, M. N., Salvador, S., & Lau, S. (2026). High-Grade Endometrial Stromal Sarcoma with NTRK Fusion and Response to Larotrectinib: A Case Report. Journal of Clinical Medicine, 15(13), 4887. https://doi.org/10.3390/jcm15134887
Vancouver
Bar-Noy T, Lozano-Franco R, Nagaria TS, Brodeur MN, Salvador S, Lau S. High-Grade Endometrial Stromal Sarcoma with NTRK Fusion and Response to Larotrectinib: A Case Report. Journal of Clinical Medicine. 2026;15(13):4887. doi:10.3390/jcm15134887
BibTeX
@article{BarNoy2026,
author = {Bar-Noy, Tomer and Lozano-Franco, Rebecca and Nagaria, Teddy S and Brodeur, Melica Nourmoussavi and Salvador, Shannon and Lau, Susie},
title = {High-Grade Endometrial Stromal Sarcoma with NTRK Fusion and Response to Larotrectinib: A Case Report},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {13},
pages = {4887},
doi = {10.3390/jcm15134887}
}
EUVIMED